Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The management of peripheral blood cytopenias in systemic lupus erythematosus Hepburn AL; Narat S; Mason JCRheumatology (Oxford) 2010[Dec]; 49 (12): 2243-54Haematological complications are frequently seen in SLE. Anaemia, leucopenias and thrombocytopenia may result from bone marrow failure or excessive peripheral cell destruction, both of which may be immune mediated. Drugs and infection are other common causes. In this review, we will focus on the diagnosis and management of immune-mediated leucopenias and thrombocytopenia in SLE. The roles of bone marrow examination and the measurement of antibodies against leucocytes and platelets are discussed. Although many patients do not require specific treatment for cytopenias in SLE, CSs remain the mainstay of treatment. Other conventional therapies include AZA, CYC and human normal immunoglobulin. More recently, MMF has found a role as a CS and CYC-sparing agent. We also review B-cell depletion in the management of thrombocytopenia associated with SLE and other novel therapies including thrombopoeitin receptor agonists.|Antibodies, Monoclonal, Murine-Derived/therapeutic use[MESH]|Antirheumatic Agents/*therapeutic use[MESH]|B-Lymphocytes[MESH]|Blood Platelets[MESH]|Bone Marrow[MESH]|Cyclophosphamide/therapeutic use[MESH]|Humans[MESH]|Lupus Erythematosus, Systemic/*complications/drug therapy[MESH]|Lymphopenia/drug therapy/*etiology[MESH]|Neutropenia/drug therapy/*etiology[MESH]|Receptors, Fc/therapeutic use[MESH]|Recombinant Fusion Proteins/*therapeutic use[MESH]|Rituximab[MESH]|Thrombocytopenia/drug therapy/*etiology[MESH]|Thrombopoietin/therapeutic use[MESH] |